Dosing has begun in a new regimen of the HEALEY ALS platform trial, its ninth, which is testing the oral therapy NUZ-001 for ...
The complex task of managing clinical trial finances is generally accepted as a cost of doing business in the pharmaceutical industry. But today, higher costs and ongoing pressures to shorten study ...
Randomized sub-trial 1 of a global adaptive platform trial of COM701 maintenance therapy in patients with relapsed platinum sensitive ovarian cancer Trial supported by strong biological rationale and ...
The HEALEY ALS Platform Trial (ClinicalTrials.gov identifier: NCT04297683) is a multicentre, double-blind, placebo-controlled adaptive Phase 2/3 clinical trial conducted by the Sean M. Healey & AMG ...
MELBOURNE, Australia, Dec. 11, 2025 /PRNewswire/ -- Neurizon® Therapeutics Limited (ASX: NUZ & NUZOA; OTCQB: NUZTF) ("Neurizon" or "the Company"), a clinical-stage biotech company dedicated to ...
In the Phase 2 Study of TPN-101 in patients with C9orf72-related ALS, TPN-101 showed clinical benefits on key clinical outcome measures, including slow vital capacity and the ALSFRS-R TPN-101 also had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results